Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 353

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 353
---
: fair value determined on the observable database for the asset or liability concerned either directly or indirectly;

Level 3: fair value determined on the basis of evaluation techniques based in whole or in part on unobservable data.

13)Revenue and government financing for research expenditures

13.1) Revenue from collaboration and licensing agreements

F-72

The Company’s revenue from collaboration and licensing agreements amounts to € 49,580 51,901 12,622

                                                                                                                                                                                  Year ended December 31,                                                             
  (in thousands of euro)                                                                                                                                                          2022 (1)                                 2023                    2024               
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Proceeds from collaboration and licensing agreements                                                                                                                                                         48,806                  50,725                 10,505  
  of which monalizumab agreement - AstraZeneca                                                                                                                                                                 22,376                   9,499                  4,404  
  of which IPH5201 agreement - AstraZeneca                                                                                                                                                                      4,677      —                       —                  
  of which preclinical molecules agreement - AstraZeneca                                                                                                                                                       17,400      —                       —                  
  of which Sanofi agreement 2016                                                                                                                                                                                4,000                   2,000                  4,000  
  of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program      —                                        18,873                  401                
  of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to the option exercise                                                  —                                        15,800                  1,700              
  of which Takeda agreement 2023                                                                                                                                                  —                                        4,553                   —                  
  of which other agreements                                                                                                                                                       353                                      —                       —                  
  Invoicing of research and development costs (IPH5201)                                                                                                                                                         1,391                   1,165                  2,060  
  Exchange gains (loss) on collaboration agreements                                                                                                                               ( 627)                                   —                       —                  
  Others                                                                                                                                                                          10                                       11                      56                 
  Revenue from collaboration and licensing agreements                                                                                                                                                          49,580                  51,901                 12,622  

a) Revenue recognition related to